COLL
Collegium Pharmaceutical Inc
21.90$
-0.7%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.1% | 49.0% | 42.7% | 46.4% | -5.6% | 46.5% | 31.2% | 38.5% | 37.5% | 59.9% | 29.5% | 35.7% | 40.8% | |
| 27.2% | 23.7% | 24.5% | 24.4% | 26.2% | 31.1% | 31.8% | 30.1% | 27.0% | 28.9% | 28.6% | 32.7% | 29.3% | |
| 5.1% | 4.7% | 5.2% | 6.9% | 4.6% | 4.2% | 6.5% | 5.8% | 4.7% | 4.7% | 5.6% | 7.2% | 5.6% | |
| 6.5% | -1.4% | -3.9% | -1.5% | -40.1% | 9.2% | -8.8% | -3.1% | -4.1% | 16.5% | -12.3% | 6.8% | 1.9% | |
| 0.0% | 0.1% | 0.4% | 0.2% | 0.2% | 0.3% | 0.4% | 0.0% | 0.1% | 0.3% | 0.1% | 0.2% | 0.2% | |
| -2.8% | -16.8% | -12.5% | -6.1% | -156.3% | -6.5% | -5.4% | -1.6% | -14.7% | -9.8% | 0.8% | -251.4% | -68.3% | |
| 36.1% | 4.7% | – | – | – | – | – | – | – | – | – | – | – | |
| -36.6% | -16.7% | -8.9% | -24.1% | -0.1% | -13.8% | 0.3% | -13.4% | 12.4% | -12.5% | 0.5% | – | – | |
| – | – | – | – | 93.3% | -8.9% | -9.1% | -8.6% | -7.7% | -10.7% | -3.7% | 146.2% | 30.6% | |
| -69.8% | -45.3% | -37.4% | -78.6% | 93.6% | -22.7% | -14.2% | -25.7% | -7.1% | -10.6% | -11.0% | 146.1% | 29.0% | |
| -18.4% | -13.1% | -7.1% | -38.4% | -68.4% | 17.4% | 11.5% | 11.3% | 15.6% | 39.5% | 19.3% | -69.6% | 1.5% | |
| 54.1% | 48.9% | 42.3% | 46.2% | -5.8% | 46.2% | 30.7% | 38.5% | 37.4% | 59.6% | 29.4% | 35.4% | 40.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.